Urology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery

This Phase 3 study is exploring suzetrigine, a new non-opioid medication, to help manage pain after ureteroscopic surgery, which is often done to treat kidney stones or other urinary tract issues. Patients with ureteral stents frequently experience discomfort, and suzetrigine could reduce the need for opioid painkillers, offering an alternative especially for those who cannot take NSAIDs. The trial is recruiting 100 participants across the United States and could lead to improved pain relief with fewer side effects.

STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy

This study is investigating whether skipping the use of ureteral stents during radical cystectomy, a surgery for bladder cancer, can lower complication rates. Ureteral stents are often used to help drain urine after surgery but can sometimes cause infections or discomfort. By comparing outcomes with and without stents, this trial involving 190 participants in the United States and Brazil aims to improve recovery experiences and reduce post-surgery infections for bladder cancer patients.

A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity

This Phase 3 trial is testing mirabegron, a medication intended to help young children with neurogenic detrusor overactivity, a bladder condition causing problems with control and high pressure. The study includes children from 6 months to under 3 years old who often require catheterization to empty their bladders. If mirabegron proves safe and effective, it may improve bladder function and quality of life for these young patients. The trial is active in multiple countries but not currently recruiting.

Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children

This Phase 4 study is examining a nerve stimulation device as a treatment for children with overactive bladder, a condition causing frequent and urgent urination. The device aims to improve bladder control without surgery or medication. The trial plans to enroll 50 participants and could offer a less invasive option that helps reduce symptoms and improves daily life for affected children.

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

This study is assessing vibegron, an oral medication, for children aged 2 to under 18 years with neurogenic detrusor overactivity who use clean intermittent catheterization. The trial aims to determine if vibegron is a safe and effective option to help manage bladder function in children, potentially offering easier treatment with fewer side effects. The study is currently recruiting at multiple sites worldwide and plans to enroll 71 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.